Amarin is a biopharmaceutical company. The Company is focused on the commercialization and development of therapeutics for cardiovascular health. The Company's main product, Vascepaź (icosapent ethyl) capsules, is for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Company refers this indication for Vascepa as the MARINE indication. Vascepa is available in the U.S. by prescription only. The Company is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol, levels which the Company refer to as mixed dyslipidemia.Data provided by Mergent, Inc.
|DR Exchange||NASDAQ Stock Market|
|Effective Date||Apr 08, 1993|
|Industry||Pharma. & Biotech.|